Connect with us
Information

Australia
North America
World

Investing News NetworkYour trusted source for investing success

North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides
Button

Precious Metals
Battery Metals
Base Metals
Energy
Critical Minerals

cse:lxx

POPULAR ARTICLES

Lexaria's Robust Patent Portfolio Continues to Grow

Lexaria's Robust Patent Portfolio Continues to Grow

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

Lexaria Announces New R&D Plans for 2026

Lexaria Announces New R&D Plans for 2026

LATEST ARTICLES

Lexaria Announces Positive Final Results from Human Pilot Study #5

Lexaria Announces Positive Final Results from Human Pilot Study #5

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Latest News

Pinnacle Closes Second and Final Tranche of Private Placement

LaFleur Minerals is On Track to Become Near-Term Gold Producer

BriaCell’s Bria-ABC Joins Roster of US-Enrolled Breast Cancer Trials

Renforth Resources Launches Research Collaboration with Queen's University on Low-Carbon Recovery of Critical Metals from the Victoria Deposit

Apex Grants Option to Acquire a Mineral Claim

Outlook Reports world

Precious Metals
- Gold
- Silver
Battery Metals
Energy
- Uranium
- Oil and Gas

Base Metals
Critical Metals
- Rare Earths
Industrial Metals
Agriculture

- Cleantech
- Emerging Tech

- Biotech
- Cannabis

- Psychedelics
- Pharmaceuticals

Featured Stocks

Gensource Potash

GSP:CC

Silver Hammer Mining

Silver Hammer Mining (HAMR:CC)

HAMR:CC

Renforth Resources

Renforth Resources (RFR:CC)

RFR:CC

Pan Global Resources

Pan Global Resources (PGZ:CC)

PGZ:CC

Miivo AI

Miivo AI (MIVO:CC)

MIVO:CC

Orosur Mining

OMI:CC

More featured stocks

Browse Companies

Precious Metals
Battery Metals
Energy

Base Metals
Critical Metals

MARKETS

COMMODITIES

CURRENCIES